Efficacy and Safety of Empagliflozin in Patients with Type 2 Diabetes Mellitus Fasting During Ramadan: A Real-World Study from Bangladesh

References

• International Diabetes Federation. IDF Diabetes Atlas. Brussels, Belgium: International Diabetes Federation; 2021.
   Google Scholar
• Lipka M, Hackett C. Why Muslims are the World Growing Religious Group. Pew Research Center; 2017.
   Google Scholar
• Center Pew Research. The future of world religions: population growth projections; 2010–2060. Available from: http://www//Pewqforum.org/2017. Accessed November 23, 2022.
   Google Scholar
• International Diabetes Federation. Diabetes and Ramadan: practical guidelines. International Diabetes Federation (IDF), in collaboration with the Diabetes and Ramadan (DAR) International Alliance; 2016. Available from: http://www.idf.org/sites/default/files/IDF-DAR-Practical-Guidelines-Final-Low.pdf. Accessed November 23, 2022.
   Google Scholar
• Hassan A, Meo SA. Diabetes during Ramadan: underestimated, under-investigated, needs more attention. Eur Rev Med Pharmacol Sci. 2014;18(22):3528–3533.
   PubMed Web of Science ®Google Scholar
• Salti I, Bénard E, Detournay B, et al. A population-based study of diabetes and its characteristics during the fasting month of Ramadan in 13 countries: results of the Epidemiology of Diabetes and Ramadan 1422/2001 (EPIDIAR) study. Diabetes Care. 2004;27:2306–2311. doi:10.2337/diacare.27.10.2306
   PubMed Web of Science ®Google Scholar
• Babineaux SM, Toaima D, Boye KS, et al. Multi-countries retrospective observational study of management and outcomes of patients with type 2 diabetes during Ramadan in 2010 (CREED). Diab Med. 2015;32(6):819–828. doi:10.1111/dme.12685
   PubMed Web of Science ®Google Scholar
• Beshyah SA. Fasting during month of Ramadan for people with Diabetes: medicine and Fiqh united at last. IJMBS. 2009;1:58–60.
   Google Scholar
• Al-Arouj M, Bouguerra R, Buse J, et al. Recommendations for management of diabetes during Ramadan. Diabetes Care. 2005;9:2301–2311.
   Google Scholar
• Al-Arouj M, Assaad-Khalil S, Buse J, et al. Recommendations for management of diabetes during Ramadan: update 2010. Diabetes Care. 2010;33(8):1895–1902. doi:10.2337/dc10-0896
   PubMed Web of Science ®Google Scholar
• International Diabetes Federation and DAR international Alliance. Diabetes and Ramadan: practical guidelines 2021. Brussels, Belgium: IDF; 2021. Available from: www.daralliance.org. Accessed November 23, 2022.
   Google Scholar
• Ahmedani MY, Zainudin SB, Alozairi ZE. Pre-Ramadan Assessment and Education. Diabetes and Ramadan Practical Guidelines 2021. International Diabetes Federation and DAR International Alliance; 2021:122–130.
   Google Scholar
• Aravind S, Tayeb KA, Ismail SB, et al. Hypoglycemia in sulphonylurea-treated subjects with type 2 diabetes undergoing Ramadan fasting: a five country observational study. Curr Med Res Opin. 2011;27(6):1237–1242. doi:10.1185/03007995.2011.578245
   PubMed Web of Science ®Google Scholar
• Hassanein M, Hanif W, Malik W, et al. Comparison of the dipeptidyl peptidase-4 inhibitor vildagliptin and the sulphonylurea gliclazide in combination with Metformin, in Muslim patients with type 2 diabetes mellitus fasting during Ramadan: results of the VECTOR study. Curr Med Res Opin. 2011;27:1367–1374. doi:10.1185/03007995.2011.579951
   PubMed Web of Science ®Google Scholar
• Al Safri S, Basiounny A, Echtay A, et al. The incidence of hypoglycemia in Muslim patients with type 2 diabetes treated with sitagliptin or a sulphonylurea during Ramadan: a randomized trial. Int J Clin Pract. 2011;65(11):1132–1140. doi:10.1111/j.1742-1241.2011.02797.x
   Web of Science ®Google Scholar
• Al Arouj M, Hassoun AAK, Medlej R, et al. The effect of vildagliptin relative to sulphonylurea in Muslim patients with type 2 diabetes fasting during Ramadan: the Virtue study. Int J Clin Pract. 2013;67(10):957–963.
   Web of Science ®Google Scholar
• Hassanein M, Abdallah K, Schweizer A. A double-blind, randomized trial including frequent physician-patient contacts and Ramadan focused advice, assessing vildagliptin and gliclazide in patients with type 2 diabetes fasting during Ramadan: the STEADFAST study. Vasc Health Risk Manag. 2014;10:319–325. doi:10.2147/VHRM.S64038
   PubMedGoogle Scholar
• Mafauzy M. Repaglinide versus glibenclamide treatment of Type 2 diabetes during Ramadan fasting. Diabetes Res Clin Pract. 2002;58:45–53. doi:10.1016/S0168-8227(02)00104-3
   PubMed Web of Science ®Google Scholar
• Jain R, Osei K, Kupfer S, Perez AT, Zhang J. Long-term safety of pioglitazone versus glyburide in patients with recently diagnosed type 2 diabetes mellitus. Pharmacotherapy. 2006;26:1388–1395. doi:10.1592/phco.26.10.1388
   PubMed Web of Science ®Google Scholar
• Hajjaji IM, Eshwihdi N, Barrowman N. Comparison of analog insulin mix 50:50 with human insulin mix 30:70 in persons with type 2 diabetes during Ramadan. Inter J Clin Pract. 2019;73(6):e13348. doi:10.1111/ijcp.13348
   Web of Science ®Google Scholar
• Häring HU, Merker L, Seewaldt-Becker E, et al. Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care. 2013;36:3396–3404. doi:10.2337/dc12-2673
   PubMed Web of Science ®Google Scholar
• Gallo LA, Wright EM, Vallon V. Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences. Diab Vasc Dis Res. 2015;12:78–89. doi:10.1177/1479164114561992
   PubMed Web of Science ®Google Scholar
• McGill JB. The SGLT2 inhibitor empagliflozin for the treatment of type 2 diabetes mellitus: a bench to bedside review. Diabetes Ther. 2014;5:43–63. doi:10.1007/s13300-014-0063-1
   PubMed Web of Science ®Google Scholar
• Zinman B, Wanner C, Lachin JM, et al.; Investigators of EMPAREG outcome. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–2128. doi:10.1056/NEJMoa1504720
   PubMed Web of Science ®Google Scholar
• Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes PubMed PMID: 28605608. N Engl J Med. 2017;377(7):644–657. doi:10.1056/NEJMoa1611925
   PubMed Web of Science ®Google Scholar
• Boehringer Ingelheim Pharmaceuticals. Jardiance (empagliflozin) tablets; prescribing information. Available from: http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing+Information/PIs/Jardiance/jardiance.pdf. Accessed November 23, 2022.
   Google Scholar
• Garvey WT, Van Gaal L, Leiter LA, et al. Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type2 diabetes. Metabolism. 2018;85:32–37. doi:10.1016/j.metabol.2018.02.002
   PubMed Web of Science ®Google Scholar
• Wan SW, Kori N, Rajoo S, et al. Switching from sulphonylurea to a sodium-glucose cotransporter 2 inhibitor in the fasting month of Ramadan is associated with a reduction in hypoglycemia. Diab Obs Metab. 2016;18(6):628–632.
   Web of Science ®Google Scholar
• Hassanein M, Echtay A, Hassoun A, et al. Tolerability of canagliflozin in patients with type2 diabetes mellitus fasting during Ramadan: results of the Canagliflozin in Ramadan Tolerance Observational Study(CRATOS). Inter J Clin Pract. 2017;71(10):e12991. doi:10.1111/ijcp.12991
   Web of Science ®Google Scholar
• Amin F, Afsana F, Nazneen NE, et al. Lifestyle practice and awareness during Ramadan fasting in Bangladesh diabetic population. BIRDEM Med J. 2016;6:26–31. doi:10.3329/birdem.v6i1.28407
   Google Scholar
• World Health Organization, Western Pacific Region. International Association for the Study of Obesity (IASO) and the International Obesity Task Force (IOTF). The Asia-Pacific Perspective: Redefining Obesity and Its Treatment. Crows Nest, NSW, Australia: Health Communications Australia; 2000.
   Google Scholar
• Liz S. New AHA recommendations for blood pressure measurement: American Heart Association Practice guidelines. Am Fam Physician. 2005;72(7):1391–1398.
   Web of Science ®Google Scholar
• Seaquist ER, Anderson J, Childs B, et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care. 2013;36:1384–1395. doi:10.2337/dc12-2480
   PubMed Web of Science ®Google Scholar
• Mange K, Matsuura D, Cizman B, et al. Language guiding therapy: the case of dehydration versus volume depletion. Ann Intern Med. 1997;127(9):848–853. doi:10.7326/0003-4819-127-9-199711010-00020
   Web of Science ®Google Scholar
• Mayo Foundation for Medical Education and Research Urinary tract infection (UTI) Mayo Clinic; September, 2022 Available from: https://www.mayoclinic.org/diseases-conditions/urinary-tractinfection/symptomscauses/syc-20353447. Accessed November 23, 2022.
   Google Scholar
• National Cancer Institute NCI Dictionary of Cancer terms Available from: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/adverse-event. Accessed November 23, 2022.
   Google Scholar
• Dogan I, Eser B, Kayadibi H. The effect of Ramadan fasting on renal functions in patients with chronic kidney disease. Turk J Biochem. 2019;44(2):189–196. doi:10.1515/tjb-2018-0373
   Google Scholar
• Lunati ME, Cimino V, Gandolfi A, et al. SGLT2-inhibitors are effective and safe in the elderly: the SOLD study. Pharmacol Res. 2022;183:106396. doi:10.1016/j.phrs.2022.106396
   PubMed Web of Science ®Google Scholar
• Bashier A, Khalifa AA, Abdelgadir EI, et al. Safety of sodium- glucose co transporter 2 inhibitors (SGLT2-I) during the month of Ramadan in Muslim patients with type 2 diabetes. Oman Med J. 2018;33(2):104–110. doi:10.5001/omj.2018.21
   Google Scholar
• Abdelgadir E, Rashid F, Basheir A, et al. Use of flash glucose monitoring system in assessing safety of the SGLT2 inhibitors during Ramadan fasting in high risk insulin treated patients with type 2 diabetes. Diab Metab Syndr. 2019;13:2927–2932. doi:10.1016/j.dsx.2019.07.055
   Web of Science ®Google Scholar
• Shao Y, Lim GJ, Chua CL, et al. The effect of Ramadan fasting and continuing sodium -glucose co-transporters-2 (SGLT2) inhibitor use on ketonemia, blood pressure and renal function in Muslim patients with type 2 diabetes. Diab Res Clin Pract. 2018;142:85–91. doi:10.1016/j.diabres.2018.05.022
   PubMed Web of Science ®Google Scholar